E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Chemotherapy-Induced Nausea and Vomiting (CINV) in breast cancer patients receiving a combination chemotherapy of doxorubicin or epirubicin with cyclophosphamide (AC-based regimen) |
Nausea e vomito indotti da chemioterapia (CINV) in pazienti con tumore della mammella che ricevono cicli multipli di doxorubicina o epirubicina con ciclofosfamide (regime a base di AC) |
|
E.1.1.1 | Medical condition in easily understood language |
Chemotherapy-Induced Nausea and Vomiting in breast cancer patients |
Nausea e vomito indotti da chemioterapia in pazienti con tumore della mammella |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10008443 |
E.1.2 | Term | Chemotherapy antiemetic prophylaxsis |
E.1.2 | System Organ Class | 10042613 - Surgical and medical procedures |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10054133 |
E.1.2 | Term | Prophylaxis of nausea and vomiting |
E.1.2 | System Organ Class | 10042613 - Surgical and medical procedures |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10008448 |
E.1.2 | Term | Chemotherapy induced emesis prophylaxis |
E.1.2 | System Organ Class | 10042613 - Surgical and medical procedures |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10049091 |
E.1.2 | Term | Chemotherapy antiemetic prophylaxis |
E.1.2 | System Organ Class | 10042613 - Surgical and medical procedures |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10008449 |
E.1.2 | Term | Chemotherapy inducted emesis prophylaxis |
E.1.2 | System Organ Class | 10042613 - Surgical and medical procedures |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10036899 |
E.1.2 | Term | Prophylaxis against chemotherapy induced vomiting |
E.1.2 | System Organ Class | 10042613 - Surgical and medical procedures |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate if the activity of one day of NEPA plus dexamethasone, to prevent chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant AC-based chemotherapy, is maintained during all the chemotherapy cycle treatment (maximum 4 cycles) |
Valutare se l’attività della singola dose di NEPA più desametasone per la prevenzione di nausea e vomito indotti da chemioterapia in pazienti con tumore della mammella che hanno effettuato una chemioterapia adiuvante a base di AC, è mantenuta durante l’intero trattamento chemioterapico (massimo 4 cicli) |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
– Women >= 18 years old. – Histologically or cytologically confirmed diagnosis of breast cancer. – Na¿f patients. – Be scheduled to receive adjuvant chemotherapy with anthracycline (doxorubicin or epirubicin) + cyclofosfamide (AC-based regimen). – ECOG Performance Status 0-2. – Body Mass Index (BMI) >= 18.5. – Written informed consent. – If women of childbearing potential age: reliable contraceptive measures must be used. – Normal hepatic function (<= 2 times the upper limit of normal for liver transaminases) and renal function (creatinine < 1.5 times the upper limit of normal). – Ability and willingness of the patient to complete the diary. |
– Donne con età >= 18 anni. – Diagnosi istologicamente/citologicamente confermata di tumore della mammella. – Paziente naïf. – Paziente candidata a ricevere chemioterapia adiuvante a base di antracicline (doxorubicina o epirubicina) con ciclofosfamide (Regime a base di AC). – ECOG Performance Status 0-2. – Indice di massa corporea (BMI) >= 18.5. – Consenso Informato Scritto. – In caso di donna in età fertile: uso di adeguati metodi contraccettivi. – Funzionalità renale ed epatica nella norma (transaminasi <= 2 volte il valore massimo; creatinina < 1,5 volte il valore massimo). – Capacità e volontà da parte del paziente di compilare il diario. |
|
E.4 | Principal exclusion criteria |
– Advanced/metastatic breast cancer. – Patients already submitted to non-AC-based chemotherapy. – Treatment with investigational medications within 30 days before NEPA. – Myocardial infarction within the last 6 months. – Documented or known hypersensitivity to 5HT3RA or NK1RA and excipients. – Uncontrolled diabetes mellitus. – Nausea and vomiting at baseline. – Chronic use of other antiemetic agent(s). – Patient’s inability to take oral medication. – Gastrointestinal obstruction or active peptic ulcer. – Pregnancy or breastfeeding – Prior malignancies at other sites except surgically treated non-melanoma skin cancer, superficial cervical cancer, or other cancer from which the patient had been disease-free for >= 5 years. – Psychiatric or CNS disorders interfering with ability to comply with study protocol. |
– Pazienti con tumore della mammella avanzato o metastatico – Pazienti già sottoposte a chemioterapia diversa da regimi a base di AC. – Trattamento con farmaci sperimentali nei 30 giorni antecedenti il trattamento con NEPA. – Infarto del miocardio negli ultimi 6 mesi. – Ipersensibilità nota o documentata ai farmaci 5-HT3 antagonisti o agli NK1 antagonisti. – Diabete mellito non controllato. – Nausea e vomito al basale. – Uso cronico di altri agenti antiemetici. – Incapacità della paziente di assumere farmaci per via orale. – Ostruzione gastrointestinale o ulcera peptica attiva. – Gravidanza o allattamento. – Neoplasie precedenti in altre sedi, ad eccezione del cancro della pelle non-melanoma trattato chirurgicamente, cancro superficiale della cervice, o altro tumore per il quale il paziente è risultato libero dalla malattia per un periodo maggiore o uguale a 5 anni. – Disturbi psichiatrici o del sistema nervoso centrale che interferiscono con la capacità di rispettare il protocollo di studio. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The rate of patients achieving and maintaining a complete response (defined as no emetic episode and no use of rescue medication) during the overall phase |
Valutare il numero di pazienti che ottengono una risposta completa, definita come assenza di episodi di vomito e d’impiego di medicazioni antiemetiche di salvataggio durante i quattro cicli di chemioterapia a base di AC. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
during the overall phase (From day 1 to day 5 after any AC-based chemotherapy administration) for a maximum 4 cycles. |
durante i quattro cicli di chemioterapia a base di AC considerando per ogni ciclo l’intero periodo di rischio di CINV (fase overall, corrispondente ai 5 giorni successivi alla somministrazione della chemioterapia). |
|
E.5.2 | Secondary end point(s) |
• rate of complete response (no vomiting and no use of rescue medication) • rate of complete control (defined as complete response with a maximum grade of mild nausea) • rate of emesis-free patients • severity of nausea graded according to Likert • patient global satisfaction with antiemetic therapy, as measured by a visual analog scale (VAS) • Safety profile. |
• Risposta completa, definita come assenza di episodi di vomito e d’impiego di terapia di salvataggio. • Controllo completo, definito come risposta completa e non più di nausea lieve. • Percentuale di pazienti libere da emesi (nessun episodio emetico). • Percentuale di nausea secondo la scala Likert (nessuna, lieve, moderata e severa). • Livello di soddisfazione globale delle pazienti alla terapia antiemetica, misurata tramite una scala visiva analogica (VAS). • Profilo di sicurezza secondo i Common Terminology Criteria for Adverse Events (CTCAE) Versione 4.3. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
During the Acute Phase (0-24 hours after chemotherapy), the Delayed (25-120 hours), the Overall (0-120 hours) phases for each cycle and separately on single days of all chemotherapy cycles, up to 4 cycles |
Durante la fase acuta (giorno della somministrazione della chemioterapia), fase ritardata (dalla 25 alla 120 ora post chemioterapia, 2-5 giorni) e nella fase overall (5 giorni, 120 ore, successivi alla somministrazione della chemioterapia) di tutti i cicli di chemioterapia a cui le pazienti saranno sottoposte, per un massimo di 4 cicli |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 41 |
E.8.5 | The trial involves multiple Member States | No |
E.8.5.1 | Number of sites anticipated in the EEA | 41 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 18 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 18 |
E.8.9.2 | In all countries concerned by the trial days | 0 |